

National shared care protocol (amended for local use in BSW):

## Riluzole for patients within adult services

### Specialist responsibilities

The content of this shared care protocol was correct as of January 2022. As well these protocols, please ensure that [summaries of product characteristics](#) (SPCs), [British national formulary](#) (BNF) or the [Medicines and Healthcare products Regulatory Agency](#) (MHRA) or [NICE](#) websites are reviewed for up-to-date information on any medicine.

- Assess the patient and provide diagnosis; ensure that this diagnosis is within scope of this shared care protocol ([section 2](#)) and communicated to primary care.
- Use a shared decision making approach; discuss the benefits and risks of the treatment with the patient and/or their carer and provide the appropriate counselling (see [section 11](#)) to enable the patient to reach an informed decision. Obtain and document patient consent. Provide an appropriate patient information leaflet.
- Assess for contraindications and cautions (see [section 4](#)) and interactions (see [section 7](#)).
- Conduct required baseline investigations and initial monitoring (see [section 8](#)).
- Initiate treatment as outlined in [section 5](#). Prescribe the maintenance treatment for at least 12 weeks and once blood results are stable, transfer to primary care.
- When transfer to primary care is appropriate, send the link to the shared care documentation to the patient's GP practice with a letter detailing the diagnosis, current and ongoing dose, any relevant test results and when the next monitoring is required. Include contact information ([section 13](#)).
- Prescribe sufficient medication to enable transfer to primary care, including where there are unforeseen delays to transfer of care.
- Conduct the scheduled reviews and monitoring in [section 8](#) and communicate the results to primary care. After each review, advise primary care whether treatment should be continued, confirm the ongoing dose, and whether the ongoing monitoring outlined in [section 9](#) remains appropriate.
- Reassume prescribing responsibilities if a woman becomes or wishes to become pregnant.
- Provide advice to primary care on the management of adverse effects if required.
- Advise primary care if treatment should be discontinued.

## Primary Care responsibilities

- Reply to the request for shared care as soon as practicable using the forms linked [here](#) (in writing or via secure email).
- If accepted, prescribe ongoing treatment as detailed in the specialists request and as per [section 5](#), taking into any account potential drug interactions in [section 7](#). Conduct the required monitoring as outlined in [section 9](#). Communicate any abnormal results to the specialist.
- Manage adverse effects as detailed in [section 10](#) and discuss with specialist team when required.
- Stop riluzole if neutropenia develops. Arrange for immediate hospital assessment if neutropenic sepsis is suspected.
- Stop riluzole and make an urgent referral to the specialist if ALT rises to 5 times the ULN or if chest x-ray finding are suggestive of interstitial lung disease.
- Refer the management back to the specialist if the patient becomes or plans to become pregnant.
- Stop treatment as advised by the specialist.

## Patient and/or carer responsibilities

- Take riluzole as prescribed and avoid abrupt withdrawal unless advised by the prescriber.
- Attend regularly for monitoring and review appointments with primary care and specialist, and keep contact details up to date with both prescribers. Be aware that medicines may be stopped if they do not attend.
- Report adverse effects to their prescriber. Seek immediate medical attention if they develop any symptoms as detailed in [section 11](#), particularly if signs of febrile illness.
- Report the use of any over the counter (OTC) medications to their prescriber and be aware they should discuss the use of riluzole with their pharmacist before purchasing any OTC medicines.
- Not to drive or operate heavy machinery if riluzole affects their ability to do so safely.
- Patients of childbearing potential should take a pregnancy test if they think they could be pregnant and inform the specialist or GP immediately if they become pregnant or wish to become pregnant.

## 1. Background

[Back to top](#)

Riluzole is indicated for extending life or the time to mechanical ventilation for patients with the amyotrophic lateral sclerosis (ALS) variant of motor neurone disease (MND). ALS is a progressive neurodegenerative disease that causes the loss of motor neurones resulting in a gradual increase in muscle weakness and muscle wasting.

Riluzole is recommended by NICE technology appraisal guidance ([TA20: Guidance on the use of Riluzole \(Rilutek\) for the treatment of Motor Neurone Disease](#)) as an option for treatment of people with ALS. It should be initiated by a neurological specialist with expertise in the management of MND.

Clinical trials have demonstrated that riluzole extends survival for patients with ALS, but only in the early stages of the disease. Further studies have not shown that riluzole is effective in the late stages of ALS. Patients in later stages of disease should be reviewed and given the opportunity to stop riluzole if they consider it appropriate.

**The safety and efficacy of riluzole has only been studied in ALS, therefore riluzole should not be use in any other form of MND.**

**Riluzole is not recommended for use in children.**

## 2. Indications

[Back to top](#)

Licensed indication: to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).

## 3. Locally agreed off-label use

[Back to top](#)

**National scoping did not identify any additional appropriate off-label indications**

## 4. Contraindications and cautions

[Back to top](#)

This information does not replace the Summary of Product Characteristics (SPC) and should be read in conjunction with it. Please see [BNF](#) & [SPC](#) for comprehensive information.

### Contraindications:

- Hypersensitivity to the active substance or to any of the excipients.

- Hepatic disease or baseline transaminases greater than 3 times the upper limit of normal (ULN).
- Pregnancy or breast-feeding.
- Acute porphyrias.

**Cautions:**

- Liver impairment: riluzole should be prescribed with care in patients with:
  - a history of abnormal liver function
  - slightly elevated serum transaminases (up to 3 times ULN), bilirubin and/or gamma-glutamyl transferase (GGT) levels
  - baseline elevations of several liver function tests (especially elevated bilirubin) should preclude the use of riluzole
- Interstitial lung disease has been reported in patients treated with riluzole.
- Neutropenia or febrile illness.
- Renal Impairment (due to lack of data).

## 5. Initiation and ongoing dose regimen

[Back to top](#)

- Transfer of monitoring and prescribing to primary care is normally after the patient has been treated for around 12 weeks, and with satisfactory investigation results for at least 4 weeks
- The duration of treatment & frequency of review will be determined by the specialist, based on clinical response and tolerability.
- All dose or formulation adjustments will be the responsibility of the initiating specialist unless directions have been discussed and agreed with the primary care clinician.
- Termination of treatment will be the responsibility of the specialist.

**Usual dose:**

50mg twice daily

**The initial maintenance dose must be prescribed by the initiating specialist.**

**Conditions requiring dose adjustment:**

None

## 6. Pharmaceutical aspects

[Back to top](#)

Route of administration:	Oral
Formulation:	50mg tablets 50mg orodispersible films 5mg/mL oral suspension
Administration details:	<p>Riluzole tablets can be crushed and dispersed in water for enteral tube administration or mixed with soft food e.g. yoghurt or puree. Give immediately or within 15 minutes. Riluzole may block enteral feeding tubes; ensure the tube is flushed well after each dose. Crushed tablets may have a local anaesthetic effect in the mouth. Crushing or splitting riluzole tablets is unlicensed.</p> <p>The orodispersible films are placed on top of the tongue; film will stick to the tongue and begin to dissolve. Once mouth is closed, saliva will normally be swallowed as orodispersible film dissolves.</p> <p>The oral suspension is suitable for administration via enteral feeding tubes. The suspension must be manually gently shaken for at least 30 seconds by rotating the bottle by 180° and the homogeneity should be visually verified.</p>
Other important information:	Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur.

## 7. Significant medicine interactions

[Back to top](#)

The following list is not exhaustive. Please see [BNF](#) or [SPC](#) for comprehensive information and recommended management.

Riluzole is metabolised by cytochrome P450 isoform 1A2 (CYP1A2) and has the potential to interact with drugs which inhibit or induce CYP1A2. The clinical relevance of these interactions has not been established, and some of these medicines are frequently used with riluzole without incident. Discuss with specialist team if there are any concerns.

- CYP1A2 inhibitors include caffeine, diclofenac, diazepam, clomipramine, imipramine, fluvoxamine, phenacetin, theophylline, amitriptyline, quinolones, mexiletine, nicergoline, rucaparib, vemurafenib, combined hormonal contraceptives
- CYP1A2 inducers include cigarette smoke, charcoal-grilled food, rifampicin, omeprazole

## 8. Baseline investigations, initial monitoring and ongoing monitoring to be undertaken by specialist

[Back to top](#)

Monitoring at baseline and during initiation is the responsibility of the specialist; only once the patient is optimised on the chosen medication with no anticipated further changes expected in immediate future will prescribing and monitoring be transferred to primary care.

### Baseline investigations:

- Liver function tests (LFTs), including serum transaminases, bilirubin and/or gamma-glutamyl transferase.
- Full blood count (FBC) including a differential white cell count (WCC).
- Urea and electrolytes.

### Initial monitoring:

- LFTs, including alanine aminotransferase (ALT), should be measured every month during the first 3 months of treatment, every 3 months during the remainder of the first year, or until transferred to primary care.
- FBC and WCC every month during the first 3 months of treatment and every 3 months during the remainder of the first year until transferred to primary care.

### Ongoing monitoring:

Routine review to assess effectiveness and ongoing appropriateness of treatment every 3- 6 months, or as clinically indicated.

After each review, advise primary care whether treatment should be continued, confirm the ongoing dose, and whether the ongoing monitoring outlined in [section 9](#) remains appropriate.

## 9. Ongoing monitoring requirements to be undertaken by primary care

[Back to top](#)

See [section 10](#) for further guidance on management of adverse effects/responding to monitoring results.

Monitoring and advice	Frequency
<ul style="list-style-type: none"> <li>• LFTs, FBC &amp; WCC</li> </ul>	Every month during the first 3 months of treatment, then every 3 months for the

remainder of the first year. NB: where monthly or quarterly monitoring is performed in secondary care prior to transfer, there is no need to repeat individual tests.

Annually after the first year.

**(If relevant) If monitoring results are forwarded to the specialist team, please include clear clinical information on the reason for sending, to inform action to be taken by secondary care.**

## 10. Adverse effects and other management [Back to top](#)

**Any serious adverse reactions should be reported to the MHRA via the Yellow Card scheme. Visit [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)**

For information on incidence of ADRs see relevant summaries of product characteristics

### Result

### Action for primary care

**As well as responding to absolute values in laboratory tests, a rapid change or a consistent trend in any value should prompt caution and extra vigilance.**

#### Altered LFTs

Elevated LFTs up to 5 times ULN

Continue riluzole and discuss with specialist. Increase monitoring frequency if ALT is elevated.

ALT rises to 5 times ULN

Stop riluzole and inform specialist. Riluzole should not normally be re-started.

#### Respiratory function

Dry cough or dyspnoea

Order chest x-ray. Stop riluzole immediately if findings are suggestive of interstitial lung disease. Inform specialist of findings.

#### Haematological parameters

Febrile illness

	Check WCC. Treat febrile illness according to local pathways. Arrange for immediate hospital assessment if neutropenic sepsis is suspected.
<b>Confirmed neutropenia</b>	Stop riluzole and inform specialist. Review patient for signs and symptoms of infection and treat or refer according to local pathways, as appropriate. Arrange for immediate hospital assessment if neutropenic sepsis is suspected.
<b>Decreased WCC to below lower limit of local reference range</b>	<p>If clinical evidence of febrile illness/neutropenia, stop riluzole and treat or refer according to local pathways, as appropriate. Arrange for immediate hospital assessment if neutropenic sepsis is suspected.</p> <p>In the absence of febrile illness or clinical signs of neutropenia, seek advice from specialist.</p>

## 11. Advice to patients and carers [Back to top](#)

The specialist will counsel the patient with regard to the benefits and risks of treatment and will provide the patient with any relevant information and advice, including patient information leaflets on individual medicines.

### **The patient should be advised to report any of the following signs or symptoms to their primary care prescriber without delay:**

- Signs or symptoms of infection, such as fever, chills or shivering, flu-like symptoms, sore throat, rashes, or mouth ulcers.
- Dry cough and/or dyspnoea.
- Signs or symptoms of liver problems, such as yellow skin or eyes (jaundice), itching all over, nausea or vomiting.

### **The patient should be advised:**

- Not to stop taking riluzole without talking to their doctor and not to share their medicines with anyone else.
- Tell their prescriber if their smoking status changes, since this may affect their medicine

- Not to drive or operate machines if riluzole affects their ability to do so safely, e.g. by causing dizziness or drowsiness, and to inform the DVLA if their ability to drive safely is affected. See <https://www.gov.uk/driving-medical-conditions> and <https://www.gov.uk/motor-neurone-disease-and-driving>.

### **Patient information**

- MND association riluzole information leaflet <https://www.mndassociation.org/app/uploads/2015/07/5A-Riluzole.pdf>
- MND Scotland riluzole fact sheet <https://www.mndscotland.org.uk/media/1824/22-riluzole-2017.pdf>
- NHS.uk. Low white blood cell count <https://www.nhs.uk/conditions/low-white-blood-cell-count/>

Patient information leaflets are also available from <https://www.medicines.org.uk/emc/search?q=riluzole>

## **12. Pregnancy, paternal exposure and breast feeding** [Back to top](#)

It is the responsibility of the specialist to provide advice on the need for contraception to male and female patients on initiation and at each review, but the ongoing responsibility for providing this advice rests with both the primary care prescriber and the specialist.

### **Pregnancy:**

Riluzole is contraindicated in pregnancy.

### **Breastfeeding:**

Riluzole is contraindicated in breast-feeding women. Very limited published evidence indicates low levels in breast milk. The UK Drugs in Lactation Advisory Service recommends caution if used, and infants should be monitored for adverse effects associated with adult use.

Information for healthcare professionals: <https://www.sps.nhs.uk/medicines/riluzole/>

### **Paternal exposure:**

Fertility studies in rats indicate slight impairment of reproductive performance and fertility at doses of 15 mg/kg/day (which is higher than the therapeutic dose), probably due to sedation and lethargy. The relevance of this to human fertility is not known.

## 13. Specialist contact information

[Back to top](#)

### SFT:

Tel: 01722 429233

[Sft.admin.neurology@nhs.net](mailto:Sft.admin.neurology@nhs.net)

Neurology dept, Salisbury District Hosp, SP2 8BJ

**GWH:** Via Cinapsis

**RUH:** Via Cinapsis or [g.chohan@nhs.net](mailto:g.chohan@nhs.net)

## 14. Additional information

[Back to top](#)

Where patient care is transferred from one specialist service or GP practice to another, a new shared care agreement must be completed. Ensure that the specialist is informed in writing of any changes to the patient's GP or their contact details.

## 15. References

[Back to top](#)

- MND association accessed via: <https://www.mndassociation.org/about-mnd/what-is-mnd/basic-facts-about-mnd/> on 20/05/21
- MND Scotland accessed via <https://www.mndscotland.org.uk/> 21/05/21
- eBNF. Riluzole. Accessed via <https://bnf.nice.org.uk/drug/riluzole.html> 21/05/21
- NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease. January 2001. Accessed via <https://www.nice.org.uk/guidance/ta20> on 21/05/21
- NICE NG42: Motor neurone disease: assessment and management. Last updated July 2019. Accessed via <https://www.nice.org.uk/guidance/ng42> on 02/09/21
- Riluzole 50 mg film coated tablets (Glentek®). Date of revision of the text 29/04/2020. Accessed via <https://www.medicines.org.uk/emc/product/10060/smpc> on 21/05/21
- Riluzole 50 mg film-coated tablets (Rilutek®) Date of revision of the text 01/01/2021. Accessed via <https://www.medicines.org.uk/emc/product/1101/smpc> on 21/05/21
- Riluzole 50 mg film-coated tablets (Ranbaxy UK Ltd). Date of revision of the text 15/02/2018. Accessed via <https://www.medicines.org.uk/emc/product/5185/smpc> on 21/05/21
- Riluzole 50mg Film-Coated Tablet (Accord-UK Ltd). Date of revision of the text 18/07/2019. Accessed via <https://www.medicines.org.uk/emc/product/2831/smpc> on 21/05/21
- Riluzole 5 mg/ml oral suspension (Teglutik®). Date of revision of the text 10/11/2019. Accessed via <https://www.medicines.org.uk/emc/product/5060/smpc> on 21/05/21

- Riluzole 50mg orodispersible film (Emylif). Date or revision of the text 19/01/2024. Accessed via [Emylif 50 mg orodispersible film - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#) on 01/10/2024
- Handbook of Drug Administration via Enteral Feeding Tubes. Riluzole. Last updated 15/02/18. Accessed via <https://www.medicinescomplete.com/#/content/tubes/c330> on 20/05/21
- NEWT Guidelines. Riluzole. Last updated October 2020. Accessed via <https://access.newtguidelines.com/R/Riluzole.html> on 20/05/21
- Specialist Pharmacy Service. Riluzole Lactation Safety Information. Last updated 3 August 2020. Accessed via <https://www.sps.nhs.uk/medicines/riluzole/> on 10/06/21
- NICE Clinical Knowledge Summaries. Neutropenic sepsis: management. Last revised March 2020. Accessed via <https://cks.nice.org.uk/topics/neutropenic-sepsis/management/management/> on 11/06/21

## • Other relevant national guidance

[Back to top](#)

- Shared Care for Medicines Guidance – A Standard Approach (RMOC). Available from <https://www.sps.nhs.uk/articles/rmoc-shared-care-guidance/>
- NHSE guidance – Responsibility for prescribing between primary & secondary/tertiary care. Available from <https://www.england.nhs.uk/publication/responsibility-for-prescribing-between-primary-and-secondary-tertiary-care/>
- General Medical Council. Good practice in prescribing and managing medicines and devices. Shared care. Available from <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices/shared-care>
- NICE NG197: Shared decision making. Last updated June 2021. <https://www.nice.org.uk/guidance/ng197/>

SCA first approved by BSW APC committee date: 23/5/24 [bswibc.prescribing@nhs.net](mailto:bswibc.prescribing@nhs.net)  
 Minor amendment 10/2024 to include orodispersible film formulation